Hanna Kim, M.S., M.D.

Contact Information

301-594-6196
9000 Rockville Pike
10 Center Drive
Building 10, Room 12S-257a
Bethesda MD 20892

Media Resources

Summary

Hanna Kim, M.S., M.D., is a board-certified pediatric rheumatologist who is focused on exploring pathogenesis and novel treatments in juvenile dermatomyositis. During her rheumatology fellowship, Dr. Kim developed a passion for clinical and translational research while studying interferon-mediated autoinflammatory diseases, novel biomarkers, pharmacokinetics, and pharmacodynamics, and safety and efficacy in a compassionate use study with an investigational drug. She went on to become a Lawrence Shulman Scholar and studied the role of interferon and activity-related biomarkers in myositis, particularly juvenile dermatomyositis. She has also been evaluating Janus kinase inhibition in a compassionate use program for refractory juvenile dermatomyositis.

Dr. Kim was appointed as an Assistant Clinical Investigator in 2020 and is also an attending physician on the NIH Pediatric Rheumatology Consultation Service. She is actively involved in a range of organizations including the American College of Rheumatology (ACR), the Childhood Arthritis Rheumatology Research Alliance, and the International Myositis Assessment and Clinical Studies Group.

She has received numerous local, national, and international awards and honors, including NIAMS Group Merit Award, ACR Distinguished Fellow Award, Rheumatology Research Foundation Pediatric Research Award, Pediatric Rheumatology European Society Young Investigator Travel Award, selection for the ACR-European League Against Rheumatism Early Investigator Exchange Program, and best abstract at the Global Conference on Myositis. Dr. Kim has also given national and international presentations.

Research Statement

The Juvenile Myositis Therapeutic and Translational Studies Unit is a research group focused on better understanding the pathogenesis of juvenile myositis, particularly inflammatory and immune mechanisms, and improved therapy. This is approached by discovery biomarker analysis utilizing broad expression such as transcriptomic and proteomic analysis in juvenile dermatomyositis, a rare autoimmune system vasculopathy with notable involvement of skin with characteristic rashes and muscle inflammation.  Another approach is looking at how biomarkers in juvenile myositis compare to Mendelian autoinflammatory disease and further analysis of juvenile myositis separated by myositis autoantibody subgroups which have some distinct patterns of features.

Regarding treatment, we investigate novel treatments in small clinical trials in juvenile myositis with the goal of establishing more targeted therapy ideally with fewer side-effects and greater efficacy.  We hope that through better understanding pathogenesis can be paired with the investigation of novel therapies that can lead to better management and improved quality of life for people with juvenile myositis.

Scientific Publications

Insights into juvenile myositis via engineered muscle.

Kim H
Nat Rev Rheumatol.
2023 Sep;
19(9).
doi: 10.1038/s41584-023-01003-6
PMID: 37495869

Improvement in Disease Activity in Refractory Juvenile Dermatomyositis Following Abatacept Therapy.

Curiel RV, Nguyen W, Mamyrova G, Jones D, Ehrlich A, Brindle KA, Haji-Momenian S, Sheets R, Kim H, Jones OY, Rider LG, Abatacept in Dermatomyositis (AID) Trial Investigators
Arthritis Rheumatol.
2023 Jul;
75(7).
doi: 10.1002/art.42450
PMID: 36657109

Performance of the 2016 ACR-EULAR Myositis Response Criteria in adult dermatomyositis/polymyositis therapeutic trials and consensus profiles.

Saygin D, Kim H, Douglas C, Erman B, Wilkerson J, McGrath JA, Oddis CV, Lundberg IE, Amato AA, García-De La Torre I, Chinoy H, Fiorentino D, Chung L, Song YW, Miller FW, Ruperto N, Vencovsky J, Aggarwal R, Rider LG, International Myositis Assessment and Clinical Studies Group (IMACS)
Rheumatology (Oxford).
2023 Nov 2;
62(11).
doi: 10.1093/rheumatology/kead110
PMID: 36929923

Performance of the 2016 ACR-EULAR myositis response criteria in juvenile dermatomyositis therapeutic trials and consensus profiles.

Kim H, Saygin D, Douglas C, Wilkerson J, Erman B, Pistorio A, McGrath JA, Reed AM, Oddis CV, Bracaglia C, van Royen-Kerkhof A, Bica B, Dolezalova P, Ferriani VPL, Flato B, Bernard-Medina AG, Herlin T, Miller FW, Vencovsky J, Ruperto N, Aggarwal R, Rider LG, International Myositis Assessment and Clinical Studies Group (IMACS) and Paediatric Rheumatology INternational Trials Organization (PRINTO)
Rheumatology (Oxford).
2023 Nov 2;
62(11).
doi: 10.1093/rheumatology/kead111
PMID: 36929918

Urine proteomics by mass spectrometry identifies proteins involved in key pathogenic pathways in patients with juvenile dermatomyositis.

Morales M, Alayi TD, Tawalbeh SM, Sydenstricker AV, Spathis R, Kim H, Nagaraju K, Hathout Y, Rider LG
Rheumatology (Oxford).
2023 Sep 1;
62(9).
doi: 10.1093/rheumatology/kead033
PMID: 36661295

Improvement in Disease Activity in Refractory Juvenile Dermatomyositis Following Abatacept Therapy.

Curiel RV, Nguyen W, Mamyrova G, Jones D, Ehrlich A, Brindle KA, Haji-Momenian S, Sheets R, Kim H, Jones OY, Rider LG, Abatacept in Dermatomyositis (AID) Trial Investigators
Arthritis Rheumatol.
2023 Jul;
75(7).
doi: 10.1002/art.42450
PMID: 36657109

Treatment escalation patterns to start biologics in refractory moderate juvenile dermatomyositis among members of the Childhood Arthritis and Rheumatology Research Alliance.

Sherman MA, Kim H, Banschbach K, Brown A, Gewanter HL, Lang B, Perron M, Robinson AB, Spitznagle J, Stingl C, Syverson G, Tory HO, Spencer CH, Tarvin SE
Pediatr Rheumatol Online J.
2023 Jan 6;
21(1).
doi: 10.1186/s12969-022-00785-5
PMID: 36609397

Updates on Juvenile Dermatomyositis from the Last Decade: Classification to Outcomes.

Kim H, Huber AM, Kim S
Rheum Dis Clin North Am.
2021 Nov;
47(4).
doi: 10.1016/j.rdc.2021.07.003
PMID: 34635298

Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy.

Kim H
Curr Opin Rheumatol.
2021 Sep 1;
33(5).
doi: 10.1097/BOR.0000000000000816
PMID: 34230439

Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis.

Kim H, Dill S, O'Brien M, Vian L, Li X, Manukyan M, Jain M, Adeojo LW, George J, Perez M, Grom AA, Sutter M, Feldman BM, Yao L, Millwood M, Brundidge A, Pichard DC, Cowen EW, Shi Y, Lu S, Tsai WL, Gadina M, Rider LG, Colbert RA
Ann Rheum Dis.
2021 Mar;
80(3).
doi: 10.1136/annrheumdis-2020-218690
PMID: 32843325

Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies.

Kim H, Gunter-Rahman F, McGrath JA, Lee E, de Jesus AA, Targoff IN, Huang Y, O'Hanlon TP, Tsai WL, Gadina M, Miller FW, Goldbach-Mansky R, Rider LG
Arthritis Res Ther.
2020 Apr 6;
22(1).
doi: 10.1186/s13075-020-02160-9
PMID: 32252809

Development of a Validated Interferon Score Using NanoString Technology.

Kim H, de Jesus AA, Brooks SR, Liu Y, Huang Y, VanTries R, Montealegre Sanchez GA, Rotman Y, Gadina M, Goldbach-Mansky R
J Interferon Cytokine Res.
2018 Apr;
38(4).
doi: 10.1089/jir.2017.0127
PMID: 29638206

Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients.

Kim H, Brooks KM, Tang CC, Wakim P, Blake M, Brooks SR, Montealegre Sanchez GA, de Jesus AA, Huang Y, Tsai WL, Gadina M, Prakash A, Janes JM, Zhang X, Macias WL, Kumar P, Goldbach-Mansky R
Clin Pharmacol Ther.
2018 Aug;
104(2).
doi: 10.1002/cpt.936
PMID: 29134648

JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.

Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, Schalm S, Murias S, Dare JA, Brown D, Stone DL, Gao L, Klausmeier T, Foell D, de Jesus AA, Chapelle DC, Kim H, Dill S, Colbert RA, Failla L, Kost B, O'Brien M, Reynolds JC, Folio LR, Calvo KR, Paul SM, Weir N, Brofferio A, Soldatos A, Biancotto A, Cowen EW, Digiovanna JJ, Gadina M, Lipton AJ, Hadigan C, Holland SM, Fontana J, Alawad AS, Brown RJ, Rother KI, Heller T, Brooks KM, Kumar P, Brooks SR, Waldman M, Singh HK, Nickeleit V, Silk M, Prakash A, Janes JM, Ozen S, Wakim PG, Brogan PA, Macias WL, Goldbach-Mansky R
J Clin Invest.
2018 Jul 2;
128(7).
doi: 10.1172/JCI98814
PMID: 29649002

Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America.

Spencer CH, Rouster-Stevens K, Gewanter H, Syverson G, Modica R, Schmidt K, Emery H, Wallace C, Grevich S, Nanda K, Zhao YD, Shenoi S, Tarvin S, Hong S, Lindsley C, Weiss JE, Passo M, Ede K, Brown A, Ardalan K, Bernal W, Stoll ML, Lang B, Carrasco R, Agaiar C, Feller L, Bukulmez H, Vehe R, Kim H, Schmeling H, Gerstbacher D, Hoeltzel M, Eberhard B, Sundel R, Kim S, Huber AM, Patwardhan A, Pediatric Rheumatologist Collaborators
Pediatr Rheumatol Online J.
2017 Jun 13;
15(1).
doi: 10.1186/s12969-017-0174-0
PMID: 28610606

Insights from Mendelian Interferonopathies: Comparison of CANDLE, SAVI with AGS, Monogenic Lupus.

Kim H, Sanchez GA, Goldbach-Mansky R
J Mol Med (Berl).
2016 Oct;
94(10).

Education

University of California at Irvine (UCI)
M.D.

Virginia Commonwealth University (VCU)
M.S.

California Institute of Technology (Caltech)
B.S.

Experience

Lawrence Shulman Scholar in Translational Research
NIAMS, NIH, Bethesda, MD

Residency in Pediatrics
George Washington University / Children’s National Medical Center

Pediatric Rheumatology Fellowship
Nemours/Alfred I. DuPont Hospital for Children (Wilmington, DE), Children’s National Health System (DC), and NIAMS, NIH.

Last Updated: